Special Topics and Prevention in Cardiology

Special Topics and Prevention in Cardiology — Internal Medicine

How it begins

Análisis exhaustivo del riesgo cardiovascular global, estrategias preventivas basadas en evidencia, síndromes de intersección orgánica y farmacología cardiovascular avanzada con enfoque en guías ACC/AHA 2023–2024 y ESC 2023.

What it covers

1. Special Topics and Prevention in Cardiology
2. Global Cardiovascular Risk — Fundamentals and Conceptual Framework
3. · Cardiovascular risk factors — updated classification
4. · Lifetime risk vs. 10 year risk
5. Scores and Cardiovascular Risk Estimation Tools
6. · Main CV risk calculators
7. · Coronary Calcium Score (CAC) — Definitive reclassifier
8. · Lp(a) — The underestimated genetic risk factor
9. Metabolic Syndrome — Pathophysiology and Cardiovascular Relevance
10. · Diagnostic criteria — IDF/AHA Consensus 2009
11. · Pathophysiology — The visceral adiposity → insulin resistance axis
12. Primary Prevention of Cardiovascular Disease
13. · Non-pharmacological interventions — Solid evidence
14. · Aspirin in primary prevention — The great debate resolved
15. Secondary Prevention — Management of Patients with Established CVD
16. · Pharmacological pillars of secondary prevention
17. Statins — Pharmacology, Clinical Evidence and Rational Use
18. · Classification by intensity
19. · Pleiotropic effects of statins
20. · Statin-induced myopathy — full spectrum
21. · Statins and diabetes mellitus — risk vs. benefit
22. Platelet Antiaggregation — Mechanisms and Clinical Strategies
23. · Pharmacology of antiplatelet agents
24. · DAPT — Optimal duration in different scenarios
25. High Blood Pressure and Cardiovascular Prevention
26. · Classification and tension objectives — ACC/AHA vs. controversy. ESC
27. · Antihypertensive drugs — Selection based on comorbidities
28. Cardiology and Diabetes Mellitus — The Therapeutic Convergence
29. · SGLT2 Inhibitors — Cardiovascular and renal benefit
30. Cardiorenal Syndrome — Classification and Integrated Management
31. · Management of patients with HF + CKD
32. Cardio-Oncology — Cardiovascular Toxicity of Oncological Treatment
33. · Cardiotoxicity due to chemotherapy
34. Heart and Pregnancy — Physiological Adaptations and Gestational Heart Disease
35. · Physiological cardiovascular changes of pregnancy
36. · Peripartum cardiomyopathy (PPCM)
37. · Aortic dissection syndrome in pregnancy
38. Atrial Fibrillation — Comprehensive Management and Anticoagulation
39. · Thromboembolic risk — CHA₂DS₂-VASc scale
40. · Frequency control vs. pace control — AFFIRM and beyond
41. Sudden Cardiac Death — Stratification and Prevention
42. · Primary prevention of SCD with ICD
43. · Chanalopathies — SCD in structurally normal heart
44. ACEI / ARA-II / ARNI — RAAS Blockade in Cardiology
45. · Renin-angiotensin-aldosterone system (RAAS) — Therapeutic targets
46. · Mineralocorticoid antagonists (MRA) — Spironolactone and Eplerenone
47. Beta-blockers in Cardiology — Differential Pharmacology
48. Oral Anticoagulation — DOACs vs. AVK and Special Scenarios
49. · Direct acting oral anticoagulants (DOACs) — Comparative pharmacology
50. · Special scenarios in anticoagulation
51. New Cardiovascular Therapies — Frontiers of Research
52. · PCSK9 inhibitors (iPCSK9) — The new era of LDL control
53. · Inclisiran — The genetic silencer of LDL
54. · Cardiovascular colchicine
55. · Oral semaglutide and the rise of dual GLP-1/GIP